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Aim: The objective of this study was to assess the distribution of hepatitis C in selected risk 
groups such as haemodialysis patients, pregnant women, healthcare workers, HIV-HCV co-in-
fected patients, patients with mental health diseases and piercing and tattoo procedures. Further-
more, it aimed at evidencing common transmitting routes and highlighting the importance of pre-
ventive measures among these groups. 
  
Methods: The literature review was conducted using online databases (Medline) with search 
query involving the keyword “hepatitis C” in conjunction with keywords describing risk groups 
such as "dialysis", or "haemodialysis", or "pregnancy", or "pregnant", or "mental health", or "tat-
too", or "piercing", or "HIV", or "health professionals”. 
 
Results: After assessing all the retrieved publications, 39 of them were considered for inclusion: 
17 on haemodialysis patients, 7 on pregnant women, 8 on HIV-HCV co-infection and 7 publica-
tions on health professionals, patients of mental health wards and piercing and tattoo procedures. 
The high rate of hepatitis C is still a high problem and in some cases it is considered as a new is-
sue, as in the case of pregnancy. Some of the transmission routes have been identified earlier, 
such as the HIV-HCV co-infection but some, such as piercing and tattoo, are becoming new 
transmission routes. Health professionals are still identified as high risk group while mental 
health patients are a potentially high risk group. 
 
Conclusion: Even though some patients are routinely screened for hepatitis C, there are indica-
tions for performing such a routine test in other groups. In almost all of the risk groups, it is ad-
vocated to use stricter preventive measures and to disseminate knowledge on risks of hepatitis C. 
 
Keywords: haemodialysis, healthcare workers, hepatitis C, human immunodeficiency virus, 
mental health diseases, piercing and tattoo, pregnancy. 
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Introduction 
Hepatitis C, as a liver infection, is caused by 
the Hepatitis C Virus (HCV), blood borne vi-
rus. The virus can cause both acute and 
chronic hepatitis, ranging in severity from a 
mild illness lasting a few weeks to a serious, 
lifelong illness. Approximately 60%-80% of 
infected people may progress to chronic liver 
disease and 20% of them will develop cirrho-
sis (1). According to WHO, globally, an esti-
mated 71 million people have chronic hepati-
tis C infection (2). An estimated 3.5 million 
people in the United States have chronic hep-
atitis C (3). 
Globally, morbidity and mortality from hep-
atitis C virus infection (HCV) is increasing. 
According to estimation from recent studies, 
more than 185 million people around the 
world are infected with hepatitis C virus (1). 
Total global prevalence of HCV is 2.5%, var-
ying from 2.9% in Africa to 1.3% in America, 
with global viremic rate 67% (118.9 million 
HCVRNA positive cases), varying from 
64.4% in Asia to 74.8% in Australasia (4). 
In Europe, the prevalence of hepatitis C 
(HCV) is estimated to be around 1.7% and in-
cludes 13 million cases, the lowest preva-
lence (0.9%) is reported in Western Europe 
(except some rural regions in South of Italy 
and Greece) and the highest prevalence in 
central Europe (3.1%) specifically in Roma-
nia and Russia (5). According to estimation 
from Global Burden of Disease study, deaths 
rate from hepatitis C was 333000 in 1990, 
499000 in 2010 and 704000 in 2013 (6). 
These cases of deaths are result of complica-
tions from HCV, including liver cirrhosis, 
hepatocellular carcinoma and liver failure 
(7). 
The following groups are at increased risk for 
HCV infection: 
 Current or former injection drug us-
ers;  
 Chronic haemodialysis patients;  
 People with known exposures to 
HCV, such as (health care workers af-
ter needle sticks involving HCV-pos-
itive blood, recipients of blood or or-
gans from a donor who tested HCV-
positive); 
 People with HIV infection;  
 Children born to HCV-positive moth-
ers;  
 Patients of mental health wards 
And also were at risk: 
 Recipients of clotting factor concen-
trates made before 1987, when less 
advanced methods for manufacturing 
those products were used;  
 Recipients of blood transfusions or 
solid organ transplants prior 1992, be-
fore better testing of blood donors be-
came available (8);  
 
Conversely, the transmission routes and epi-
demiology include: 
 Intravenous drug use; 
 Non-intravenous recreational drug 
exposure; 
 Healthcare procedures;  
 Accidental exposure; 
 Mother to child vertical transmission;  




Search and study identification 
The aim of the study was to identify, through 
literature review, studies addressing the fol-
lowing: 
- cases of Hepatitis C,  
- most common transmitting route,  
- the importance of preventive 
measures, 
among several risk groups such as: haemodi-
alysis patients, pregnant women, healthcare 
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workers, HIV-HCV co-infected patients, pa-
tients with mental health diseases and practi-
tioners of piercing and tattoo. 
Articles published were identified by litera-
ture survey in online database Medline 
through PubMed interface, using keywords:  
"hepatitis C"  
AND 
("dialysis" OR "haemodialysis" OR "preg-
nancy" OR "pregnant" OR "mental health" 
OR "psychiatry" OR "tattoo" OR "piercing" 
OR "HIV" OR "health professionals" OR 
"health workers"). 
From the search query, 1788 publications 
were identified and from these only original 
publications were included. The following 
data were excluded from our analysis: data 
with unclear definition of HCV infection, du-
plicated data, all short communications or re-
views. Next, the remaining 688 publications 
were selected and after removing publica-
tions without abstract, there were left 617 of 
them. After reading abstracts of 617 publica-
tions we selected 150 publications that ful-
filled our research interests. All 150 publica-
tions were studied and publications that dealt 
with detailed treatments, or included other 
groups of interests were excluded. Finally, 
we selected 39 publications for analysing and 
presenting their results, as presented in Fig-
ure 1. 
 
Figure 1. Search and study identification 
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Overview of the results 
After a full text screening, as presented in 
Figure 2, a total of 39 articles were consid-
ered for inclusion: 17 on haemodialysis pa-
tients, 7 on pregnant women, 8 on HIV-HCV  
 
 
coinfection and in total 7 publications on 
health professionals, patients of mental 
health wards and piercing and tattoo proce-
dures. In following sections, each group will 
be discussed and in the end of each section, a 
short conclusion will be presented. 
 





Results on Haemodialysis / HCV 
From 17 publications on HCV and haemodi-
alysis, 10 of the publications included on 
their results prevalence of HCV on Haemodi-
alysis centres, while 7 other publications in-
cluded on their result other findings or asso-
ciation of HCV with other factors. For HCV, 
prevalence estimates that were considered 
representative for haemodialysis centres 
were available for 10 countries as presented 
in Table 1. A prospective study conducted in 
Japan in 2016 (9) included 41 haemodialysis 
centres, with total of 2986 haemodialysis pa-
tients. The aim of the study was to screen for 
HCV antibody, and HCV RNA, but as well 
to determine genotype of hepatitis C and the 
treatment of HCV patients. In its findings, au-
thors have reported that 5.02% of patients 
were HCV Ab positive and from this number 
72.31% were HCV RNA positive. Another 
interesting conclusion of the study, was that 
62.1% of tested patients were HCV genotype 
1 and that the combined therapy of Daclatas-
vir and Asunaprevir was effective at HCV 
positive patients in haemodialysis. Another 
study performed in Japan, but this time a ret-
rospective one (10), included 3064 patients 
on haemodialysis. The aim of the study was 
to find the association of hepatitis C virus in-
fection with the prognosis of chronic haemo-
dialysis patients. The results of the study sug-
gested that of those patients, 14.0% were 
HCV RNA positive, while 2.4% were 
HBsAg positive and 0.3% were double posi-
tive. Also in the study, it was reported that by 
2010, 49% of haemodialysis patients were 
deceased. From that percentage, 60% of them 
were HCV RNA positive, and 47% HCV 
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ducted in Brazil (11) that included 798 hae-
modialysis patients, with the aim of determi-
nation of prevalence of HCV infection and 
genotypes in patients undergoing haemodial-
ysis. The study found that performing ELISA 
test, 8.4% of the patients resulted HCV posi-
tive, while 86.1% of them had determined vi-
ral genotype 1 and 11.6% determined geno-
type 2 and 2.3% determined genotype 3. One 
of the suggestions of the authors was to 
strengthen the control strategies for hepatitis 
C in haemodialysis centres. A cross-sectional 
study conducted in China in 2013 (12), in-
cluded 2120 patients on haemodialysis and 
409 patient partners. This study investigated 
the prevalence and risk factors of HCV and 
HBV infection and the distribution of HCV 
genotypes among haemodialysis patients and 
their spouses. Authors findings were that 
6.1% of the patients were anti-HCV positive, 
4.6% of them were HCV RNA and 7.0% of 
them resulted in HBsAg positive. Regarding 
the prevalence of their partners, it resulted 
that 0.5% of them were anti-HCV positive, 
while 0.2% RNA HCV positive and 4.2% 
HBsAg positive. Some of the risk factors that 
authors have mentioned were: the duration of 
dialysis and blood transfusion. The predomi-
nant genotype was 1b with 89% while 2a had 
7.7% and genotype 3a, 3b, 6a each by1.1%. 
Authors’ suggestion, due to the persistence of 
nosocomial infection, were strict infection 
control measures to be strengthened with the 
aim of reducing the transmission of HCV. 
Another prospective study, that involved 170 
patients on haemodialysis, was performed in 
US (13), with the aim to overview the inci-
dence and preventive measures for HCV in 
the haemodialysis centre. The study resulted 
in finding 5.4% new HCV cases, from which 
4 cases were genotype 1a, 2 cases of geno-
type 1b. The other 37.6% of old cases, 29 
cases were genotype 1a, 16 cases were geno-
type 1b, and 2 cases were genotype 3a. 
Cross sectional survey in Sudan included 353 
patients of haemodialysis, aiming to deter-
mine the seroprevalence and risk factors for 
hepatitis C and hepatitis B in their dialysis 
centres (14). Their finding resulted in 16 
cases that were HBsAg positive and 30 cases 
that were anti-HCV positive. The long dura-
tion of dialysis and surgical intervention, 
were most common risk factors, related to in-
fection. In the Middle East, authors (15) con-
ducted a prospective investigation, to find the 
impact of an identical isolation policy on in-
cidence of nosocomial HCV infection in hae-
modialysis centre. Study was conducted in 
two phases, phase one involving 189 patients 
and phase two involving 198 patients af-
fected of haemodialysis. Their study resulted 
in finding 83 (43.9%) phase one patients with 
anti HCV positive, while the remaining 106 
(56.1%) patients resulted as anti HCV nega-
tive. An interesting fact is the correlation be-
tween HCV positivity and the dialytic age (of 
83 patients who had positive results for anti-
HCV antibodies had a mean dialytic age of 
48.5 ± 14.2 months, compared with 25.0 ± 
8.6 months among the 106 anti-HCV-nega-
tive patients). In phase II, they had similar re-
sults, 85 (42.9%) of 198 patients had anti-
HCV positive results, and 113 (57.1%) con-
tinued to have a negative status for anti-HCV 
antibodies. Interesting relation between 
phase one and two is the addition of two new 
anti-HCV positive cases (none of them be-
longing to the added 9 after phase one), that 
occurred over 12 months of study period, 
leading to an HCV seroconversion rate of 
1.01% per year (15). Netherlands conducted 
a nationwide prospective study on the preva-
lence and incidence of Hepatitis C virus in-
fections among dialysis patients in 1996 (16). 
In 34 haemodialysis centres, a total of 2281 
patients were included, dividing the research 
into two phases: the first phase with 2281 pa-
tients – where the HCV RNA positive rate 
was 2.9%, and the second phase after one 
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year with the sample of 2286 patients, where 
3.4% of the cases were HCV RNA positive. 
Main risk factors were also identified by the 
study, and those being: haemodialysis before 
1992, kidney transplantation before 1994, 
birth in other countries, and receiving dialysis 
abroad during vacations. Another cross sec-
tional study was conducted in Canada, aim-
ing to study Hepatitis C prevalence and risk 
factors in dialysis population, with 336 pa-
tients included in the study (17). The study 
resulted in finding that prevalence of anti-
HCV antibody was 6.5% (22/336), 77.2% 
(17/22) of cases that were anti-HCV positive 
resulted HCV RNA positive.  Another pro-
spective study was conducted with 128 pa-
tients in USA, with findings of 25% of them 
positive HCV EIA (18), but tests were not 
specific because in 6 cases it was detected 
and resulted negative, which speaks about 
past infection. It is known that PCR remains 
the only reliable test to determine the pres-
ence of the virus.  
 
 
Table 1. Hepatitis C in haemodialysis centres 
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(11) 2013 Brazil Prospective 798 
HCV anti-
body 
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HCV Ab posi-
tive cases 4.6% 
were HCV 
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HCV RNA 
positive  
(18) 1998 USA Prospective 128 
HCV anti-
body 
25% /  
 
 
In relation to haemodialysis patients, some 
other studies were conducted to find the con-
nection between haemodialysis patients and 
HCV and other risk factors. Since that con-
nection is believed to be of importance, find-
ings of those studies are briefly presented in 
the following paragraphs. One of the studies 
investigated bleeding epidemic that has 
erupted on September-October 2013, in hae-
modialysis unit in Vietnam, involving 119 
patients with 9 positive HCV cases and 9 pos-
itive HBV cases. Authors found that HCV 
prevalence in the epidemic was 6%, which is 
7.5 times higher than in the vast population 
of Vietnam (19).  Another retrospective study 
conducted in USA found correlation between 
HCV and hepatocellular carcinoma (HCC), 
when checking 32860 HCV cases, that re-
sulted in 262 cases with HCC (20). HCC was 
12 times more common in cases of cirrhosis, 
3 times more frequent in cases of alcohol con-
sumption and 1.3 times higher in cases of di-
abetes, with the likelihood of HCC increasing 
with age. Another correlation, this time lin-
ear, between incidence and prevalence, was 
found in a study in France, concluding that 
doubling the value of P(C) doubles the inci-
dence of cases with hepatitis C (21). A pro-
spective study conducted in Spain, found ini-
tial prevalence (p <0.0001) and time (p 
<0.0001) emerging as independent variables 
associated with the decrease of HCV preva-
lence (22). Authors of another study, con-
ducted in France, found that HCV serocon-
version was associated with the number of 
hemodialysis sessions undergone on a ma-
chine shared with or in the same room as a 
patient who was anti-HCV (genotype 2a/2c) 
positive (23).  A cross sectional study in USA 
found by using multivariate logistic regres-
sion analysis, that the longer duration of re-
ceiving dialysis associated with a history of 
intravenous drug use, were the only risk fac-
tors that remained independently associated 
with HCV seropositivity (24). Authors of a 
study in France found that overall, HCV 
RNA became undetectable in 16 patients 
(69.6%) 1 month after starting IFN-a therapy 
and in 21 patients (91.3%) at the end of treat-
ment (25). 
 
Results on Pregnancy /HCV  
Conducting the literature review, 7 studies 
that presented a relation between HCV infec-
tion and pregnancy were included, as shown 
in Table 2.  A research conducted in Pakistan 
(26), enrolled 119 cases of pregnant women 
with HCV positive, and 238 control cases, 
from the total of 5621 pregnant women, of 
whom 5339 were screened. Their result 
showed that iatrogenic exposure (health care 
injections, hospitalizations and pregnancies) 
are the major risk factors for transmission of 
HCV among pregnant women. Therefore, the 
authors call for strengthening the prevention 
aspect of the hepatitis control program to fo-
cus on behaviour change for reducing injec-
tion reuse and overuse. A study in the USA, 
which included 1013 obstetric patients iden-
tified that use of intravenous drugs resulted 
as the fastest risk factor (27) in HCV. Authors 
emphasize that the epidemiologic data are 
consistent with sexual and parenteral modes 
of transmission, however, according to them 
routine screening for hepatitis C is not advo-
cated. Another study in the USA, with 599 
pregnant hospitalised women, identified 
 
Rashiti-Bytyçi A, Ramadani N, Kalaveshi A, Muçaj S, Gashi L, Rashiti P. Hepatitis C in several risk 




P a g e  9 | 19 
4.3% were HCV positive, from which 3 pos-
itive HIV cases, and 2 of them had coinfec-
tion with hepatitis C. Another correlation be-
tween hepatitis B and hepatitis C, resulted in 
1 coinfection from 5 cases with hepatitis B 
(28). Another study in Italy, reported that 
HCV transmission was higher in mothers 
with fluctuating ALT levels (31/154; 20.1%) 
when compared with mothers with normal 
ALT levels (35/292; 12%). The HCV trans-
mission was the highest in the group of moth-
ers with constantly raised ALT levels (8/31; 
25.8%) (29). Vertical transmission of HCV 
was investigated in three studies. The first 
study (30), had as a subject 2447 HCV preg-
nant women, from whom 78 women (3.2%) 
were anti-HCV positive, 60 women (2.5% or 
77% of all cases of positive anti-HCV) were 
positive HCV-RNAs. Regarding the new-
borns, 60 of them (50%) remained HCV-
RNA negative, throughout 22 of them 
(36.7%) were RNA-HCV positive in one case 
and 8 of them (13.3%) were RNA-HCV pos-
itive at least in the two following tests and 
only 2 children (3.3%) remained positive 
RNA-HCV, testing after 8 to 24 months (30).  
The second vertical transmission study was 
conducted in Ireland with 36 HCV pregnant 
women (31). From the study resulted that all 
36 cases were positive when tested with Elisa 
and 26 women (76%) were PCR positive for 
HCV genotype 1. In terms of vertical trans-
mission only one child resulted positive when 
tested with PCR HCV (31). The third study 
conducted with 3712 pregnant women, re-
sulted in 35 (0.94%) women that were anti-
HCV positive and out of this number 20 
women (57%) were HCV RNA positive (32). 
The vertical transmission rate was 5%, where 
only one new-born of 29 of maternal RNA 
HCVs positive resulted HCV RNA even after 
12 months of birth that speaks for HCV per-
sistent infection (32). 
 
Table 2. Hepatitis C related to pregnancy 
 








(26) 2006 Pakistan 
Case con-
trol 
5339 Elisa HCV 119 (2%) were HCV positive 
(27) 1992 USA Prospective 1005 
HCV anti-
body 
2.28% (N = 23) were HCV posi-
tive 
(28) 1994 USA Prospective 599 Elisa HCV 4.3% were HCV positive 













HCV transmission was higher in 
mothers with 
fluctuating ALT levels (31/154; 
20.1%) when compared 
with mothers with normal ALT 
levels (35/292; 12%) 




HCV RNA  
8 of 60 (13.3%) infants born to 
HCV-RNA positive mothers ac-
quired HCV infection, but only 2 
(3.3%) were still infected by the 
end of follow-up. 







The 36 cases were positive Elisa 
and 26 (76%) were PCR positive 
for HCV genotype 1b. In terms of 
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vertical transmission only one 
child resulted positive PCR HCV. 




HCV RNA  
Out of 3712 women, 35 (0.94%) 
were anti-HCV positive and out 
of this number 20 (57%) were 
HCV RNA positive. The vertical 
transmission rate was 5%. 
 
Results on HIV / HCV coinfection 
Regarding the relation between the HCV and 
HIV, a number of research papers, presented 
in Table 3, discussed the coinfection, while 
proving unfortunately that the problem is on 
the rise. The first study reviewed, was a pro-
spective study performed in Ghana, where 
from 1520 HIV infected cases, HCV RNA 
test was performed in all HBsAG positive 
subjects (n=236) and a random subset of 
HBsAg negative subjects (n=172), which re-
sulted in 4 positive cases (3 cases of genotype 
2 and 1 case of genotype 1). From these four 
infected cases surgical procedures and blood 
transfusion procedure was reported as an im-
portant risk factor for HCV infection (33). 
In 2018, a study in Spain was performed in-
cluding 322 patients with Hepatocellular car-
cinoma in patients with HIV/HCV coinfec-
tion (34). The study aimed finding the rela-
tionship between the use of antiviral agents 
and the risk of HCC in HIV/Hepatitis C co-
infected patients. As a result, 42 (13%) of pa-
tients occurred after sustained virological re-
sponse. It is interesting to mention that after 
using direct antiviral agents in HIV/HCV co-
infected patients, the frequency of hepatocel-
lular carcinoma was not increased. A study 
conducted in Canada between 2005 and 
2015, examined the relationship between 
HIV-seropositivity and having access to a 
physician for regular HCV care (35). In total, 
1627 HCV-positive cases were eligible for 
analysis; from whom 582 (35.8%) were HIV-
positive at baseline and 31 (1.9%) became 
HIV-positive during follow-up. Their results 
demonstrated a positive relationship between 
HIV-seropositivity and having access to a 
physician for regular HCV care, which is par-
tially explained through increased frequency 
of engagement in health care (35). In 11 Eu-
ropean countries, data were used for perform-
ing retrospective and cross sectional study 
with 229 HCV / HIV cases of children and 
young adults (36). That resulted in 63% of 
cases that were infected with hepatitis C ver-
tically, 7% of them were infected with hepa-
titis C as nosocomial infection, 17% with 
drug use and 13% of them has no data about 
the way of infection. Study also reveals that 
among infected patients with hepatitis C, a 
high number of patients with progressive 
liver disease was present, so it suggests the 
importance of improving monitoring proce-
dures and offering earlier HCV proper treat-
ment (36). A study in 9 emergency units in 
England, in 2014, during “Going Viral” cam-
paign, 7807 patients were tested (37). That 
resulted in 39 HCV infected persons (15 
newly diagnosed), 17 HIV infected persons 
(six newly diagnosed), and 15 HBV infected 
persons (11 newly diagnosed). It also re-
vealed that those aged 25–54 years had the 
highest prevalence: 2.46% for HCV, 1.36% 
for HIV and 1.09% for HBV.  Another study 
performed with 4950 participants in some re-
gions in China resulted with HIV and HCV 
prevalence of Yanyuan county were 0.06% 
and 0.15%, respectively. HCV prevalence of 
Muli county was 0.06% HCV and none was 
found to be HIV positive (38). Another im-
portant finding from this survey was that HIV 
epidemics has not spread from high risk 
groups to the general population. 
A systematic review and meta-analyses of 10 
studies (39), 2382 infants, were included in 
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an analysis of HCV-infected mothers (de-
fined by anti-HCV and antibody assays) with 
and without concomitant HIV infection. The 
risk estimate of HCV vertical transmission 
was 2.82 from anti-HCV positive/HIV posi-
tive co-infected mothers compared with anti-
HCV positive/ HIV negative mothers. This 
finding revealed that the risk of HCV vertical 
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Table 3. HIV – HCV coinfection 
 





(33) 2014 Ghana 
Prospective 
study 
From 1520 infected HIV, all 
HBsAg-positive subjects (n 
= 236) and a random subset 
of HBsAg-negative subject 
(n = 172) were screened for 
HCV RNA 
HCV RNA 4 positive cases 
(34) 2018 Spain 
Prospective 
study 












1627 HCV positive cases 
HCV RNA, 
HIV test 
582 (35.8%) were 
HIV-positive at 










229 children and young 
adults with HIV/HCV 
HCV RNA, 
HIV RNA 
63% of cases  in-
fected with hepatitis 
C vertically, 7% in-
fected with hepatitis 
C as nosocomial in-
fection, 17% drug 
use and 13% no data 
(37) 2014 England Prospective 
9 units of emergency de-




39 HCV infections 
(15 newly diag-
nosed), 17 HIV in-
fections (six newly 
diagnosed), and 15 
HBV infections (11 
newly diagnosed). 






HIV and HCV prev-
alence of Yanyuan 
county were 0.06% 
and 0.15%, respec-
tively. HCV preva-
lence of Muli county 
was 0.06% HCV and 
none was found to 
be HIV positive 
(39) 2003 USA 
A systematic 
review  




Risk estimate of 
HCV vertical trans-






(40) 2014 USA 
Review of rec-
ommendations  
/ / / 
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Results on health workers, tattoo and pierc-
ing procedures, patients of mental units / 
HCV 
Three of seven studies involved in the survey 
and presented in Table 4, revealed that health 
practitioners are the major risk group of get-
ting HCV while giving care to their positive 
HCV patients.  Study on health care profes-
sionals approach to patients with hepatitis C 
revealed that during treatment they use 
stricter measures to protect themselves from 
infection (40). In the study, a questionnaire 
was sent to 3675 health professionals and in 
the end 1347 completed questionnaires were 
taken for analysis. As a final result, the study 
suggests that focusing education strategies on 
changing health practitioners’ attitudes to-
ward people with hepatitis C, injecting drug 
users, and infection control guidelines rather 
than concentrating solely on medical infor-
mation might ultimately improve patient 
care. Another study conducted in USA, re-
vealed that HIV and HCV infection was 
transmitted to health care workers from nurs-
ing home patients, when they dealt with these 
infections through non-intact skin exposure. 
In these cases, the infection may have been 
prevented by consistent, unfailing use of bar-
rier preventive measures (41). In Italy the re-
search that was performed in 9 haemodialysis 
centres with 1002 patients for detecting in-
fection with hepatitis B, Hepatitis C and HIV, 
resulted with prevalence of HBsAg in pa-
tients of 5.1%; HCV antibody 39.4%; anti-
bodies to HIV 0.1%. Another important re-
sult in this study emphasized that health pro-
fessionals in haemodialytic centres has 4000 
and 8000 times lower for HIV than for hepa-
titis B and hepatitis C, respectively (42). Re-
garding the relation of HCV with mental ill-
ness, in the review are included two studies. 
The first study, with 293 veterans with HCV 
positive, resulted with 93% of the partici-
pants had at least one psychiatric problem 
and 73% had more than 2 mental disorders 
(43). The authors concluded that the routine 
screening for underlying psychiatric and sub-
stance use disorders and early treatment in-
tervention before initiating antiviral therapy 
is essential. Another study with 931 patients 
with mental illness, revealed that among this 
group there is a high number of infected per-
sons with HIV, hepatitis B and hepatitis C - 
3.1% with HIV,  23.4% cases with hepatitis 
B and 19.6% cases with HCV (44). A big 
problem, authors found, is the large number 
of undetected cases with hepatitis C, and de-
lay in detection is related to treatment delay 
and also might be a source of infection to oth-
ers. Regarding the relation of HCV and tat-
tooing or piercing procedures, two studies are 
included. The first study, of 10 case-control 
studies, 6 reported no increased risk of HCV 
infection from tattooing when they controlled 
for injected drug use and other risk behav-
iours, and 2 studies reported a 2–3 times 
higher risk for HCV infection when the tattoo 
was received in nonprofessional settings 
(45). Another study about knowledge of tat-
too practitioners about HCV and transmis-
sion revealed that from 35 employees, 34 
were aware of guidelines and body piercing 
(46). The average number of piercing proce-
dures during the week was 5.5. Study showed 
that body-piercing practitioners had inade-
quate training, and lacked knowledge and un-
derstanding of HCV transmission, infection 
control, and universal precautions. As a con-
clusion health care practitioners are in high 
risk for getting HCV infection from infected 
patients, so they should stricter measures. 
Also it was identified high rate of HCV infec-
tion among patient with mental health dis-
eases, and large number of undetected cases, 
that is a sign for occurring epidemics inside 
mental health wards. Another conclusion re-
lated to piercing and tattoo procedures re-
vealed that risk of HCV infection is signifi-
cant among risk groups. Also lack of 
knowledge about HCV transmission among 
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body piercing and tattoo practitioners could 
be a risk factor on rise. 
 
Table 4. Hepatitis C related to health care practitioners, mental disease patients,  
tattoo and piercing procedures 
 







Focusing education strategies on 
changing health practitioners’ atti-
tudes toward people with hepatitis 
C, injecting drug users, and infec-




2003 USA Case report 
HIV and HCV transmission from 
the patient to the HCW appears to 





1993 Italy Prospective 
The risk of acquiring infection was 
calculated to be 8000 times lower 




2005 USA Prospective 
93% of the patients had a current or 
past history of at least 1 psychiatric 




2001 USA Prospective 
Prevalence rates of HBV (23.4%) 
and HCV (19.6%) were approxi-
mately 5 and 11 times the overall es-






2015 USA Meta –analyse 
Risk of HCV infection is significant, 
especially among high-risk groups 
(adjusted odds ratio, 2.0–3.6), when 
tattoos are applied in prison settings 






Cross - sectional 
survey 
Body piercing practitioners had in-
adequate training, and lacked 
knowledge and understanding of 
HCV transmission, infection con-




As for the first part of the research on haemo-
dialysis, presented in Table 1, most of the 
studies were of prospective nature, indicating 
the importance of following up the relations 
between the haemodialysis and HCV. Less 
than half of the studies had a bigger sample 
than 1000 patients. The timing of haemodial-
ysis and the risk of infection with hepatitis C 
virus appear to be in the right proportion, as 
the years of haemodialysis increase and the 
risk of acquiring hepatitis C infection in-
creases. The laboratory tests in almost all of 
the studies, included HCV antibody and/or 
HCV RNA but considering that HCV RNA 
test is more expensive, in developing coun-
tries like Sudan, only the HCV antibody test 
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was conducted, which can’t differentiate be-
tween an active infection versus a chronic or 
previously acquired infection. But, still the 
HCV antibody test, can provide an overview 
of the infected population with hepatitis C.  
This is also confirmed by the results of three 
studies (9,12,17) where over 70% of HCV Ab 
positive cases were found to be HCV RNA 
positive. Generally, most of the studies sug-
gest stronger preventive measures and 
stronger infection control strategies on hae-
modialysis centres. 
The second part of the research, dealing with 
relation between hepatitis C and pregnancy, 
presented in Table 2, most of the studies were 
of prospective nature. Injections (intravenous 
drugs) and hospitalization were identified as 
most common pathways of infection of preg-
nant women with HCV. Other studies fo-
cused on vertical transmission, identified that 
new-borns were infected with HCV. These 
results emphasise the importance of routine 
screening for HCV during pregnancy. 
The part of the research dealing with hepatitis 
C and HIV co-infection, identified several 
publications, where most of them conducted 
prospective studies. The laboratory tests in-
cluded HCV RNA and HIV test. Several 
studies call for routine screening in order to 
find out if they are infected but as well to of-
fer earlier and proper treatment. 
The last part of the research included health 
care practitioners, mental health patients and 
tattoo and piercing procedures. According to 
the publications, health care practitioners are 
in high risk for getting HCV infection, from 
infected patients, so they should use stricter 
measures. Also, a high rate of HCV infection 
among patient with mental health diseases 
was observed, and large number of unde-
tected cases, that is a sign for occurring epi-
demics inside mental health wards. Mean-
while, related to piercing and tattoo proce-
dures, research revealed that risk of HCV in-
fection is significant among risk groups. Also 
lack of knowledge about HCV transmission 
among body piercing and tattoo practitioners 
could be a risk factor on the rise. 
 
Conclusion  
After discussing the most important aspects 
presented in all 39 papers, the authors’ view-
points are as follows: 
- The most common test used to 
identify hepatitis C is HCV RNA, 
even though as an expensive test, 
sometimes Elisa / HCV antibody 
test can provide a valuable over-
view on infection. 
- Most of the studies were of pro-
spective nature, indicating the im-
portance of following up the dis-
ease. 
- Almost every study suggests 
stronger preventive measures and 
stronger control on haemodialysis 
centres. 
- Unfortunately, the hepatitis C in-
cidence is on the rise. 
In line with these viewpoints, it is of para-
mount importance to emphasize that the rou-
tine screening can be life changing in finding 
out new cases and educating the population 
about the importance of preventive measures, 
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